Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 5;10(1):e23172.
doi: 10.1016/j.heliyon.2023.e23172. eCollection 2024 Jan 15.

FDA-approved heterocyclic molecules for cancer treatment: Synthesis, dosage, mechanism of action and their adverse effect

Mossaraf Hossain  1 , Imran Habib  1 , Koustav Singha  1 , Anoop Kumar  2
Affiliations
Review

FDA-approved heterocyclic molecules for cancer treatment: Synthesis, dosage, mechanism of action and their adverse effect

Mossaraf Hossain et al. Heliyon. .

Abstract

As the incorporation of heterocycles increases the physical characteristics and biological activity of pharmacological molecules, heterocyclic scaffolds are commonly discovered as common cores in a wide spectrum of biologically active drugs. In the contemporary context, many heterocycles have arisen, playing vital roles in diverse pharmaceutical compounds that benefit humanity. Over 85 % of FDA-approved medication molecules contain heterocycles, and most importantly, numerous heterocyclic medicinal molecules indicate potential benefits against a range: of malignancies. The unique flexibility and dynamic core scaffold of these compounds have aided anticancer research. These medications are used to treat cancer patients by targeting particular genes, enzymes, and receptors. Aside from the drugs that are now on the market, numerous forms are being researched for their potential anti-cancer activity. Here in this review, we classified some molecules and biologically active heterocycles containing anticancer medicinal moieties approved by the FDA between 2019 and 2021 based on their use in various forms of cancer. We will focus on those that are suitable for cancer treatment, as well as the essential biochemical mechanisms of action, biological targets, synthetic methods, and inherent limiting considerations in their use.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
The active ingredients containing heterocyclic fragments of the top 5 small molecule drug brands by retail sales in 2022 worldwide.
Fig. 2
Fig. 2
The worldwide estimated number of new incidents of all cancers, distributed by region, considering all ages and both genders in 2020.
Fig. 3
Fig. 3
Worldwide crude incidence rates by type of cancer in all ages and both genders in 2020 (Excluding Non-melanoma skin cancers).
Fig. 4
Fig. 4
Comparison of the crude incidence and mortality rates of males and females of all ages in the world in 2020 (Excluding Non-melanoma skin cancers).
Scheme 1
Scheme 1
Synthesis of Alpelisib.
Scheme 2
Scheme 2
Synthesis of Tucatinib.
Scheme 3
Scheme 3
Synthesis of Entrectinib.
Scheme 4
Scheme 4
Synthesis of Capmatinib.
Scheme 5
Scheme 5
Synthesis of Pralsetinib.
Scheme 6
Scheme 6
Synthesis of Tepotinib.
Scheme 7
Scheme 7
Synthesis of Mobocertinib.
Scheme 8
Scheme 8
Synthesis of Lurbinectedin.
Scheme 9
Scheme 9
Synthesis of Trilaciclib.
Scheme 10
Scheme 10
Synthesis of Darolutamide.
Scheme 11
Scheme 11
Synthesis of Relugolix.
Scheme 12
Scheme 12
Synthesis of Sotorasib.
Scheme 13
Scheme 13
Synthesis of Selpercatinib.
Scheme 14
Scheme 14
Synthesis of Avapritinib.
Scheme 15
Scheme 15
Synthesis of Ripretinib.
Scheme 16
Scheme 16
Synthesis of Tivozanib.
Scheme 17
Scheme 17
Synthesis of Erdafitinib.
Scheme 18
Scheme 18
Synthesis of Zanubrutinib.
Scheme 19
Scheme 19
Synthesis of Umbralisib.
Scheme 20
Scheme 20
Synthesis of Selinexor.
Scheme 21
Scheme 21
Synthesis of Pemigatinib.
Scheme 22
Scheme 22
Synthesis of Tazemetostat.
Scheme 23
Scheme 23
Synthesis of Fedratinib.
Scheme 24
Scheme 24
Synthesis of Decitabine using 5-azacytosine.
Scheme 25
Scheme 25
Synthesis of Cedazuridine from Gemcitabine.
Scheme 26
Scheme 26
Synthesis of Selumetinib.
Scheme 27
Scheme 27
Synthesis of Piflufolastat F 18.
Image 1
Image 2
Image 3
Image 4
Image 5
Image 6
Image 7
Image 8
Image 9
Image 10
Image 11
Image 12
Image 13
Image 14
Image 15
Image 16
Image 17
Image 18
Image 19
Image 20
Image 21
Image 22
Image 23
Image 24
Image 25
Image 26
Image 27
Image 28
Image 29
Image 30
Image 31
Image 32
Image 33
Image 34
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Martins P., Jesus J., Santos S., Raposo L.R., Roma-Rodrigues C., Baptista P.V., Fernandes A.R. Heterocyclic anticancer compounds: recent advances and the paradigm shift towards the use of nanomedicine's tool box. Molecules. 2015;20(9):16852–16891. - PMC - PubMed
    1. Pearce Simon. The importance of heterocyclic compounds in anti-cancer drug design. Drug Discovery. 2017;67
    1. Whitesell J.K. C2 symmetry and asymmetric induction. Chem. Rev. 1989;89(7):1581–1590.
    1. Peerzada M.N., Hamel E., Bai R., Supuran C.T., Azam A. Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development. Pharmacol. Ther. 2021;225 - PubMed
    1. Sachdeva H., Khaturia S., Saquib M., Khatik N., Khandelwal A.R., Meena R., Sharma K. Oxygen-and sulphur-containing heterocyclic compounds as potential anticancer agents. Appl. Biochem. Biotechnol. 2022;194(12):6438–6467. - PubMed
-